Strata Critical Medical (SRTA) Shares Up > 16% Pre-Market Post-1Q26 Earnings
Strata’s 1Q26 results beat estimates, with revenue of $67.4 million up 87.4% yoy and topping consensus estimates of $64.95 million.
(New York, New York) Strata Critical Medical (NASDAQ: SRTA) announced first quarter 2026 results this morning (May 6) – Q1 revenue rose 87.4% year-over-year to $67.4 million, beating consensus estimates of $64.95 million.
Image courtesy of Strata Critical Medical.
The full earnings release can be found here.
Strata’s logistics revenue and gross profit grew 2.4% and 29.9% year-over-year, respectively, in Q1 2026, and clinical revenue and gross profit saw sequential growth of 12.7% and 29.2%, respectively in Q1 2026 versus Q4 2025, according to today’s press release from Strata.
Q1 2026 net income from continuing operations came in at $2.4 million.
Strata shares (SRTA) are up 16.6% at $5.62 pre-market as of 9.05am ET.
** Not investment advice; neither The FLY Report nor FLYJETS – nor any associated individual – is a registered investment adviser.
